Stereotactic body radiotherapy with sintilimab and bevacizumab biosimilar in anti-PD-1 refractory hepatocellular carcinoma: the ReUNION-1 phase 2 trial

Journal:

Nature Communications

Published:

2025-12-18

DOI:

10.1038/s41467-025-67528-4

Affiliations:

6

Authors:

14

Go to article

Institutions	Authors	Share
Wuhan Union Hospital, HUST, China	11.000000 11.000000	0.79
Simcere Pharmaceutical Group, China	2.000000	0.14
Eastern Hepatobiliary Surgery Hospital (EHBH), SMMU, China	0.500000	0.04
National Center for Liver Cancer, China	0.500000	0.04

Interested in Oncology and Carcinogenesis?